Tilmaamaha Macluumaadka Lenvatinib ee Kansarka - AASraw
AASraw waxay soo saartaa Cannabidiol (CBD) budada iyo Hemp Saliida Muhiimka ah!

Lenvatinib

 

  1. Taariikhda Lenvatinib
  2. Waa maxay Lenvatinib?
  3. Mashruuca Lenvatinib ee waxqabadka
  4. Maxaa Lenvatinib Loogu Adeegsadaa?
  5. Maxay Tahay Waxyeelooyinka Aan Karan Kari Karo Marka Aad Isticmaasho Lenvatinib?
  6. Natiijooyinka Caafimaadka ee Lenvatinib (Ansixinta FDA)
  7. Xagee ku hayaa Lenvatinib?
  8. Daawooyinka La Xiriira: Lenvatinib Mesylate (CAS: 857890-39-2)
  9. Halkeen ka iibsan karnaa Lenvatinib khadka tooska ah?

 

Taariikhda Lenvatinib

Tijaabada caafimaad ee wajiga koowaad ee bukaanka kansarka waxaa la sameeyay 2006. [8] Tijaabada wajiga III ee lagu daaweynayo bukaanka kansarka tayroodhka wuxuu bilaabmay Maarso 2011.

Lenvatinib waxaa la siiyay xaalad daroogo agoon ah oo loogu talagalay daaweynta noocyada kala duwan ee kansarka tayroodhka ee aan ka jawaabin radioiodine ee Maraykanka iyo Japan ee 2012 iyo Yurub ee 2013.

Bishii Febraayo 2015, US FDA ayaa oggolaatay lenvatinib daaweynta horusocodka, shucaaca radioiodine ee kaladuwan kansarka tayroodhka. Bishii Maajo 2015, Hay'adda Dawooyinka Yurub (EMA) waxay u oggolaatay daawada isla tilmaam.

Bishii Meey 2016, FDA ayaa oggolaatay (oo ay weheliso everolimus) si loogu daweeyo kansarka kelyaha ku dhaca ee kelyaha ka dib mid ka hor daaweynta anti-angiogenic.

Bishii Ogosto 2018, FDA waxay ogolaatay lenvatinib daaweynta safka koowaad ee dadka qaba cudurka kansarka 'hepatocellular carcinoma' (HCC).

 

Waa maxay Lenvatinib?

Lenvatinib (CAS:417716-92-8) waa xannibaadaha loo yaqaan 'receptor tyrosine kinase (RTK) inhibitor' kaas oo xakameynaya howlaha kinase ee istiraatiijiyadda koritaanka xididdada xididdada dhiigga (VEGF) ee VEGFR1 (FLT1), VEGFR2 (KDR), iyo VEGFR3 (FLT4). Lenvatinib sidoo kale wuxuu xakameynayaa RTK-yada kale ee ku lug lahaa cudurka anjiogenesis, koritaanka burooyinka, iyo horumarka kansarka marka lagu daro shaqadooda caadiga ah ee gacanta, oo ay kujiraan soo dhaweynta fibroblast factor (FGF) receptors FGFR1, 2, 3, and 4; platelet plate factor factor receptor alpha (PDGFRα), QALABKA, iyo RET. Daawooyinkaan tyrosine kinases (RTKs) ee kuyaala xuubka unugga waxay door muhiim ah ka ciyaaraan firfircoonida dariiqooyinka gudbinta calaamadaha ee ku lugta leh qawaaniinta caadiga ah ee unugyada, sida kordhinta unugyada, hijrada, apoptosis iyo kala duwanaanta, iyo cudurka anjiogenesis, lymphogenesis koritaanka burooyinka iyo horumarka kansarka. Gaar ahaan, VEGF waxaa loo aqoonsaday inuu yahay xakameeye muhiim u ah jir ahaanshaha jir ahaaneed iyo jir-dilista iyo muujinta kordhinta VEGF waxay la xiriirtaa saadaal xumo liidata noocyo badan oo kansar ah

Lenvatinib waxaa loogu talagalay daaweynta bukaanada qaba soo noqnoqoshada ama metastatic, horumarka, shucaaca iodine (RAI) - cillad kala sooca kansarka tayroodh. Bukaannada badankood ee qaba kansarka tayroodhku waxay leeyihiin saadaal aad u wanaagsan oo daaweyn ah (98% heerka badbaadada 5 sano) ee ku lug leh qalliinka iyo daaweynta hoormoonka. Si kastaba ha noqotee, bukaanada qaba RAI-diidmada kansarka tayroodhka, xulashooyinka daaweynta ayaa xaddidan oo saadaashu waa liidataa, taasoo horseed u ah riixitaanka horumarinta daaweyn badan oo la beegsanayo sida lenvatinib.

 

Lenvatinib Farsamaynta ficilka

Lenvatinib waa daaweeye tyrosine kinase (RTK) horjoogsade oo xakameynaya howlaha kinase ee istiraatiijiyadda koritaanka xididdada xididdada dhiigga (VEGF) VEGFR1 (FLT1), VEGFR2 (KDR), iyo VEGFR3 (FLT4). Lenvatinib sidoo kale wuxuu xakameynayaa RTK-yada kale ee ku lug lahaa cudurka anjiogenesis, koritaanka burooyinka, iyo horumarka kansarka marka lagu daro shaqadooda caadiga ah ee gacanta, oo ay kujiraan soo dhaweynta fibroblast factor (FGF) receptors FGFR1, 2, 3, and 4; platelet plate factor factor receptor alpha (PDGFRα), QALABKA, iyo RET.

AASraw waa soo saaraha xirfadlaha ah ee Lenvatinib.

Fadlan halkan guji si aad u hesho macluumaadka xigashada: Nala soo xiriir

 

Waa maxay Lenvatinib Loo Isticmaalay? 

En Lenvatinib waxaa loo isticmaalaa in lagu daaweeyo nooc ka mid ah thyroid kansarka soo noqday ama ku faafay qaybaha kale ee jidhka oo aan lagu daaweyn karin iodine-ka shucaaca.

En Lenvatinib sidoo kale waxaa loo isticmaalaa everolimus (Afinitor, Zortress) si loogu daaweeyo kansarka kalyaha (RCC, nooc ka mid ah kansarka ka bilaabma kilyaha) ee dadka horey loogu soo qaatay daawo kale oo kiimiko ah.

En Lenvatinib sidoo kale waxaa loo isticmaalaa in lagu daaweeyo kansarka hepatocellular (HCC; nooc ka mid ah kansarka beerka) oo aan lagu daweyn karin qalliin.

❹ Lenvatinib sidoo kale waxaa loo isticmaalaa pembrolizumab (Keytruda) si loogu daaweeyo nooc cayiman kansarka endometrium (dahaarka ilmo-galeenka) oo ku faafay qaybaha kale ee jirka ama ka sii daray intii lagu jiray ama kadib daaweynta daawooyinka kiimikada ama aan lagu daaweyn karin qalliin ama shucaac daaweyn ah.

En Lenvatinib wuxuu ku jiraa nooc daawo ah oo loo yaqaan kinase inhibitors. Waxay ku shaqeysaa iyadoo la xakameynayo ficilka borotiinka aan caadiga ahayn ee tilmaamaya unugyada kansarka inay tarmaan. Tani waxay kaa caawinaysaa joojinta faafitaanka unugyada kansarka.

 

Waa maxay Shalkan Ecilladaha Mayay I Nsi toos ah Wsi ay u Waad Isticmaashaa Lenvatinib?

Dhibaatooyinka soo raaca ee ah inaad u sheegto dhakhtarkaaga ama xirfadlahaaga daryeelka caafimaadka sida ugu dhakhsaha badan ee suurtogalka ah:

Reactions Dareen-celinta xasaasiyadda sida finanka maqaarka, cuncun ama cuncun, barar wejiga, dibnaha, ama carrabka

▪ dhibaatooyinka neefsashada

▪ xabad xanuun ama wadno garaac

Zz dawakhaad

▪ dareemid suuxdin ama madax-fudayd, dhicitaan

▪ madax xanuun

Pressure dhiig kar

▪ qalal

Calaamadaha iyo astaamaha dhiig-baxa sida saxarada dhiigga ama madow, saxarada tarry; kaadi casaan ama madow-madow; tufaya dhiig ama walax bunni ah oo u eg qaxwada; dhibco casaan ah oo maqaarka ah; nabar aan caadi ahayn ama dhiig baxa isha, ciridka, ama sanka

Calaamadaha iyo astaamaha isbeddelka halista ah ee garaaca wadnaha ama garaaca wadnaha sida xanuunka laabta; dawakhaad; garaaca wadnaha oo dhakhso ah ama aan caadi ahayn; wadna garaac; dareemid miyir beelid ama madax wareer, dhicitaan; dhibaatooyinka neefsashada

▪ calaamadaha iyo astaamaha dhaawaca kilyaha sida kaadida oo dhib ku ah ama kaadida oo isbadasha

▪ calaamadaha iyo astaamaha dhaawaca beerka sida kaadi madow oo jaalle ah ama bunni ah; dareen xanuun guud ama astaamo u eg hargab; saxaro midab khafiif ah leh; cunto xumo; lallabbo caloosha xanuun midigta sare; aan caadi ahayn oo daciif ah ama daallan; indhaha ama maqaarka oo huruud noqda

▪ calaamadaha iyo astaamaha kaalshiyamka hooseeya sida muruqyada oo xanuuna ama murqo xanuun; xabad xanuun; dawakhaad; dareemid miyir beelid ama madax wareer, dhicitaan; wadna garaac; dhibaatooyinka neefsashada; ama dhakhso, garaaca wadnaha oo aan joogto ahayn

▪ calaamadaha iyo astaamaha istaroogga sida isbeddelada aragga; jahwareer; dhibaato hadalka ama fahamka; madax xanuun daran; kabuubis lama filaan ah ama daciifnimo wejiga, gacanta ama lugta ah; dhibaato socodka; dawakhaad; luminta dheelitirka ama isuduwidda

▪ calool xanuun

▪ barar lugaha ama anqawyada

Ually aan caadi ahayn oo daciif ah ama daalan

 

Dhibaatooyinka soo raaca ee aan inta badan u baahnayn daryeel caafimaad (u sheeg dhakhtarkaaga ama xirfadlaha daryeelka caafimaadka haddii ay sii socdaan ama dhib ku yihiin):

▪ shuban

▪ laab xanuun

Ite cunto xumo

So nabarrada afka

▪ murqo xanuun

Lallabbo, matagid

▪ miisaan lumis

Liiskani ma sharxi karo dhammaan waxyeelooyinka suurtagalka ah. Wac dhakhtarkaaga si aad uga hesho talo caafimaad wixii ku saabsan dhibaatooyinka soo raaca. Waxaad ku soo wargelin kartaa waxyeellooyinkaaga FDA 1-800-FDA-1088.

 

Lenvatinib

 

Lenvatinib Natiijooyinka Caafimaadka(Ansixinta FDA)

The Oggolaanshaha FDA ee Lenvatinib wuxuu ku saleysnaa xarun-kala-duwan, kala-soocid, laba-indhoole, tijaabinta xakamaynta placebo ee maaddooyinka 392 oo leh soo noqnoqosho maxalli ah ama shucaac-shucaac leh oo iodine-diidmo ah thyroid kansarka iyo caddaynta shucaaca ee horumarka cudurka 12 bilood gudahood ka hor intaan la kala soocin, oo lagu xaqiijiyay dib-u-eegista shucaaca madaxbannaan. Mawduucyadu waxay heleen Lenvatinib 24 mg hal mar maalintii (n = 261) ama placebo (n = 131) illaa iyo inta cudurku ka socdo. Natiijooyinka daraasadda waxay muujiyeen maadooyinka Lenvatinib-la daweeyay waxay ku noolaayeen dhexdhexaad dhexdhexaad ah 18.3 bilood iyadoon cudurkoodu sii socon (sii-socosho la'aan), marka la barbardhigo dhex-dhexaad ah 3.6 bilood maadooyinka la siiyay placebo. Intaa waxaa sii dheer, 65% maadooyinka lagu daaweeyay Lenvatinib waxay arkeen hoos u dhaca cabirka burooyinka, marka loo eego 2% maadooyinka helay placebo.

AASraw waa soo saaraha xirfadlaha ah ee Lenvatinib.

Fadlan halkan guji si aad u hesho macluumaadka xigashada: Nala soo xiriir

 

Xagee ku hayaa Lenvatinib?

Ka fogow gaaritaanka carruurta.

Ku kaydi inta u dhexeysa 20 iyo 25 darajo C (68 iyo 77 darajo F). Iska tuur wixii daawo ah ee aan la isticmaalin ka dib taariikhda uu dhacayo.

XUSUUS: Warqadani waa soo koobitaan. Ma dabooli karto dhammaan macluumaadka suurtagalka ah. Haddii aad su'aalo ka qabtid dawadan, la hadal dhakhtarkaaga, farmashiistahaaga, ama daryeel caafimaad bixiyahaaga.

 

Daawooyinka la xiriira: Lenvatinib Misylate (CAS: 857890-39-2)

Lenvatinib mesylate (CAS: 857890-39-2) waa aaladda loo yaqaan 'synthetic', oo afka laga heli karo oo looga hortago cuncunka xididdada koritaanka cuncunka xididka 2 (VEGFR2, oo sidoo kale loo yaqaan KDR / FLK-1) tyrosine kinase oo leh firfircoonaan firfircoonida antineoplastic. E7080 wuxuu xannibayaa VEGFR2 firfircoonida VEGF, taasoo keentay joojinta wadada wareejinta calaamadaha VEGF, hoos u dhaca socdaalka unugyada xididdada dhiigga iyo kordhinta, iyo apoptosis cell endothelial vascular.

Lenvatinib mesylate waa cusbo methanesulfonate ah oo lagu helo falcelinta lenvatinib oo leh hal xabbo oo u dhiganta methanesulfonic acid. Daawada kahortaga badan iyo daroogada agoonta ah ee loo isticmaalo (sida cusbada mesylate) ee daaweynta noocyada kala duwan ee kansarka tayroodhka ee aan ka jawaabin radioiodine. Waxay leedahay door ahaan EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, a fibroblast factor factor receptor antagonist, daroogo agoon ah, cunsur soosaaraha soo-dhaweynta xidid-qaadaha ee soo-dhaweynta iyo wakiilka antineoplastic. Waxay ka kooban tahay lenvatinib (1+).

 

Lenvatinib mesylate waa la oggol yahay in loo isticmaalo keligiis ama daawooyinka kale si loogu daaweeyo:

Cin Kansarka 'endometrial carcinoma' oo horumarsan isla markaana ka sii daraya ka dib daweyno kale. Waxaa loo isticmaalaa pembrolizumab bukaanada kansarkoodu uusan aheyn microsatellite xasiloonida-sare (MSI-H) ama qalad dayactir la'aanta (dMMR) lagumana daaweyn karo qalliin ama daaweynta shucaaca.

Cin Hepatocellular carcinoma (nooc ka mid ah kansarka beerka). Waxaa loo isticmaalaa daaweynta koowaad ee bukaanada aan cudurkooda looga saari karin qalliin.

Cin Kansarka unugyada 'Renal cell carcinoma' (nooc ka mid ah kansarka kalyaha) oo horumarsan. Waxaa loo isticmaalaa everolimus bukaanada horey uhelay daaweynta angiogenesis inhibitor.

Cancer Kansarka qanjirka 'thyroid' ee bukaanjiifka qaaska ah ee qaba xanuun soosocda, soo noqnoqda, ama metastatic ah oo aan ka jawaabin daaweynta lagu shubo iodine-ka shucaaca.

Isticmaalkan waxaa lagu ansixiyay Barnaamijka Ansixinta ee Dardargelinta ee FDA. Xaalad ogolaansho ah, tijaabinta xaqiijinta (yada) waa inay muujiso in lenvatinib mesylate ay siiso faa'iido caafimaad bukaanadan. Lenvatinib mesylate sidoo kale waxaa lagu baranayaa daaweynta noocyada kale ee kansarka.

 

Xagee Ka Iibsan Karnaa Lenvatinib online?

Waxaa jira alaab-qeybiyeyaal / soosaarayaal badan oo budada lenvatinib ah oo suuqa ku jira, helitaanka midka dhabta ah waa mid aad muhiim ugu ah dhammaan dadka u baahan badeecadan si deg deg ah. Markii aan go'aansanayno inaan ka iibsano budada lenvatinib suuqa, waxaan u baahanahay inaan waxbadan kabarano, ogaano sida loo isticmaalo iyo habka wax u qabadka, qatar kasta oo jirta markaan qaadano budada lenvatinib…. Intaas waxaa sii dheer, qiimaha iyo tayada waa inay ahaadaan waxyaabaha aan ka walwalsanahay ka hor intaanan iibsan.

Ka dib markii aan ka baarnay xog uruurinta suuqa, marka la barbardhigo alaab-qeybiyeyaal badan, AASraw waxay u muuqataa xulasho wanaagsan dadka doonaya inay waxbadan iibsadaan budada lenvatinib, waxsoosaarkooda si adag ayaa loo xakameeyay iyada oo loo marayo xaalada cGMP, tayada waa lala socon karaa wakhti kasta waxaana laga yaabaa inay bixiyaan dhammaan warbixinnada baaritaanka markaad dalbato. Sida qiimaha lenvatinib budada / qiimaha, waa inay macquul tahay, indhahayga. Sababtoo ah waxaan ka helay qiimayaal badan alaab-qeybiyeyaal kala duwan, marka la barbardhigo tayada, waxaan u maleynayaa in aasraw uusan noqon doonin xulasho xun.
Faahfaahin dheeraad ah, ku soo dhowow inaad la hadasho AASraw!

 

Tixraaca

[1] H. Erdem, C. Gündogdu, iyo S. Üipal, "Isku xidhka E-cadherin, VEGF, muujinta COX-2 ee xuduudaha saadaalinta ee papillary thyroid carcinoma," Experimental and Molecular Pathology, vol. 90, maya. 3, p. 312-317, 2011.

[2] M. Yagi, S. Kato, Y. Kobayashi et al., "Xakamaynta xaddidan ee cunsur-soo-saaraha koritaanka cuncunka (PDGF) qaboojiyeyaasha autophosphorylation iyo dhacdooyinka gacanta ee PDGF-dhexdhexaadinta oo ah quinoline derivative," Experimental Cell Research, vol. 234, maya. 2, bogga 285-292, 1997.

[3] P. Soares, J. Lima, A. Preto et al., "Isbedelada hidaha ee carcinomas tayroodh ah oo si liidata u kala duwan oo aan loo kala soocin," Xilligan. Genomics, vol. 12, maya. 8, p. 609-617, 2011.

[4] MM Moura, BM Cavaco, V. Leite. RAS proto-oncogene oo ku jira medullary thyroid carcinoma. Kansarka 'Endocr Relat Cancer', 22 (5) (2015), p. R235-R252.

[5] BR Haugen, SI Sherman Wax ka beddelka hababka bukaanka qaba kansarka tayroodh ee kala duwan. Endocr Rev, 34 (3) (2013), pp. 439-455.

[6] M. Xing, D. Clark, H. Guan, iyo al. Tijaabinta isbeddelka BRAF ee tijaabooyinka tijaabada ganaax-ciribtirka qanjirka 'thyroid' ee loogu talagalay qalliinka hore ee qalliinka kansarka qanjirka 'thyroid'. J Clin Oncol, 27 (18) (2009), pp. 2977-2982.

[7] SR Wedge, DJ Ogilvie, M. Dukes, iyo al. ZD6474 wuxuu joojiyaa calaamadaha cunsuriyadda koritaanka xididdada xididdada dhiigga, angiogenesis, iyo koritaanka burooyinka kadib maamulka afka. Kansarka Kansarka, 62 (16) (2002), pp. 4645-4655.

[8] SI Sherman, EEW Cohen, P. Schoffski, iyo al. Wax ku oolnimada cabozantinib (Cabo) ee bukaanjiifka medullary thyroid (MTC) ee qaba RAS ama isbeddelada RET: Natiijooyinka ka soo baxa daraasadda wejiga III [abstract]. J Clin Oncol, 31 (Qalabka 15.) (2013) abstr 6000.

[9] SI Sherman, LJ Wirth, JP Droz, iyo al. Motesanib diphosphate ee horumarka kaladuwanaanta kansarka tayroodh. N Engl J Med, 359 (1) (2008), pp. 31-42.

[10] K. Okamoto, K. Kodama, K. Takase, iyo al. Waxqabadyada ka-hortagga antitumor ee bartilmaameedka multi-tyrosine kinase inhibitor lenvatinib (E7080) ee ka dhanka ah moodooyinka burooyinka ee RET hiddo-wadaha ah. Cancer Lett, 340 (1) (2013), pp. 97-103.

[11] E. Cabanillas, M. Schlumberger, B. Jarzab, iyo al. Tijaabada 2 wajiga ah ee lenvatinib (E7080) ee horumarsan, horumarsan, shucaac-ku-kicinta, kala-duwanaanta kansarka tayroodhka: natiijooyinka caafimaad iyo qiimeynta biomarker Cancer, 121 (16) ( 2015), bog. 2749-2756.

0 jecel yahay
6854 Views

Waxaa kaloo laga yaabaa

Comments are closed.